Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

SUMMARY: BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Diabetes Endocrinol
Hlavní autoři: Tsai, Joy N, Lee, Hang, David, Natalie L, Eastell, Richard, Leder, Benjamin Z
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980341/
https://ncbi.nlm.nih.gov/pubmed/31447409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(19)30255-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky